{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:29:51Z","timestamp":1762475391850,"version":"build-2065373602"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T00:00:00Z","timestamp":1675036800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.jdcr.2023.01.019","type":"journal-article","created":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T13:10:03Z","timestamp":1675429803000},"page":"77-80","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Expanding the clinical phenotype of nuclear matrix protein 2 antibody-positive dermatomyositis"],"prefix":"10.1016","volume":"33","author":[{"given":"Michelle","family":"Toker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roya S.","family":"Nazarian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pooja","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bijal","family":"Amin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedict","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jdcr.2023.01.019_bib1","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/annrheumdis-2011-200697","article-title":"Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy","volume":"71","author":"Ichimura","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.jdcr.2023.01.019_bib2","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1007\/s10067-021-05667-x","article-title":"Association of anti-NXP2 antibody with clinical characteristics and outcomes in adult dermatomyositis: results from clinical applications based on a myositis-specific antibody","volume":"40","author":"Yan","year":"2021","journal-title":"Clin Rheumatol"},{"issue":"12","key":"10.1016\/j.jdcr.2023.01.019_bib3","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1002\/acr.23210","article-title":"Cutaneous and systemic findings associated with nuclear matrix protein 2 antibodies in adult dermatomyositis patients","volume":"69","author":"Rogers","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"10.1016\/j.jdcr.2023.01.019_bib4","doi-asserted-by":"crossref","first-page":"R97","DOI":"10.1186\/ar3822","article-title":"Anti-MJ\/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis\/dermatomyositis","volume":"14","author":"Ceribelli","year":"2012","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"10.1016\/j.jdcr.2023.01.019_bib5","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1002\/art.38093","article-title":"Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1\u03b3","volume":"65","author":"Fiorentino","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.jdcr.2023.01.019_bib6","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1093\/jalm\/jfac038","article-title":"The utility of myositis specific antibodies in clinical practice","volume":"7","author":"Biddle","year":"2022","journal-title":"J Appl Lab Med"},{"issue":"11","key":"10.1016\/j.jdcr.2023.01.019_bib7","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1002\/acr.23188","article-title":"Antinuclear matrix protein 2 autoantibodies and edema, muscle disease, and malignancy risk in dermatomyositis patients","volume":"69","author":"Albayda","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"8","key":"10.1016\/j.jdcr.2023.01.019_bib8","doi-asserted-by":"crossref","first-page":"922","DOI":"10.3899\/jrheum.211234","article-title":"Clinical heterogeneity of patients with antinuclear matrix protein 2 antibody-positive myositis: a retrospective cohort study in China","volume":"49","author":"Li","year":"2022","journal-title":"J Rheumatol"},{"issue":"7","key":"10.1016\/j.jdcr.2023.01.019_bib9","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jamaneurol.2020.0673","article-title":"Association of dermatomyositis sine dermatitis with anti-nuclear matrix protein 2 autoantibodies","volume":"77","author":"Inoue","year":"2020","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1016\/j.jdcr.2023.01.019_bib10","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jaad.2019.05.105","article-title":"Dermatomyositis: diagnosis and treatment","volume":"82","author":"Waldman","year":"2020","journal-title":"J Am Acad Dermatol"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512623000310?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512623000310?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:24:40Z","timestamp":1762475080000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512623000310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":10,"alternative-id":["S2352512623000310"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2023.01.019","relation":{},"ISSN":["2352-5126"],"issn-type":[{"type":"print","value":"2352-5126"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expanding the clinical phenotype of nuclear matrix protein 2 antibody-positive dermatomyositis","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2023.01.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier on behalf of the American Academy of Dermatology, Inc. This is an open access..","name":"copyright","label":"Copyright"}]}}